The regulation of the complexes between cyclins and cyclin-dependent protein kinases (CDKs) is critical for the passage through the cell cycle phases. Accumulating evidence showed that the alteration of cyclin-CDK pathway is frequently observed in a wide variety of carcinomas, haematological malignancies, and sarcomas. Owing to their role in tumour cell proliferation, CDKs represent attractive targets for anticancer therapies. In particular, some CDKs inhibitors are currently used in the clinical setting in breast cancer and several clinical trials are currently underway to test the efficacy of combining CDK inhibitors, especially CD4/6, with different drugs in different tumour types. Despite their efficacy, numerous results have confirmed that CDK inhibitors in monotherapy have a limited antitumor effect that could be increased when combined with other targeted agents.
The goal of this Research Topic is to improve the knowledge, at the preclinical level, of the effects of these new combinations in solid tumors. In particular, one of the main problems related to the use of synthetic drugs in cancer treatment is the appearance of acquired resistance, by chronic exposure, to the compound that is responsible for failure of the therapy. For this reason, it is urgent to develop novel combined strategies to improve the efficacy of the CDK inhibitors and prevent or overcome resistance.
The scope of the present article collection is to update the knowledge about the mechanism of action of the CDK inhibitors and to propose novel therapeutic strategies to improve their efficacy. We welcome submissions of original research, reviews, minireview, focusing on:
1. Molecular mechanisms of action of specific CDK inhibitors in selected tumor types.
2. The rationale to improve the efficacy of CDK inhibitors with combination strategies.
3. Study of the resistance mechanisms to CDK inhibitors and strategies to prevent or overcome them.
4. Biological effects and molecular mechanisms of action of new CDK inhibitors
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
The regulation of the complexes between cyclins and cyclin-dependent protein kinases (CDKs) is critical for the passage through the cell cycle phases. Accumulating evidence showed that the alteration of cyclin-CDK pathway is frequently observed in a wide variety of carcinomas, haematological malignancies, and sarcomas. Owing to their role in tumour cell proliferation, CDKs represent attractive targets for anticancer therapies. In particular, some CDKs inhibitors are currently used in the clinical setting in breast cancer and several clinical trials are currently underway to test the efficacy of combining CDK inhibitors, especially CD4/6, with different drugs in different tumour types. Despite their efficacy, numerous results have confirmed that CDK inhibitors in monotherapy have a limited antitumor effect that could be increased when combined with other targeted agents.
The goal of this Research Topic is to improve the knowledge, at the preclinical level, of the effects of these new combinations in solid tumors. In particular, one of the main problems related to the use of synthetic drugs in cancer treatment is the appearance of acquired resistance, by chronic exposure, to the compound that is responsible for failure of the therapy. For this reason, it is urgent to develop novel combined strategies to improve the efficacy of the CDK inhibitors and prevent or overcome resistance.
The scope of the present article collection is to update the knowledge about the mechanism of action of the CDK inhibitors and to propose novel therapeutic strategies to improve their efficacy. We welcome submissions of original research, reviews, minireview, focusing on:
1. Molecular mechanisms of action of specific CDK inhibitors in selected tumor types.
2. The rationale to improve the efficacy of CDK inhibitors with combination strategies.
3. Study of the resistance mechanisms to CDK inhibitors and strategies to prevent or overcome them.
4. Biological effects and molecular mechanisms of action of new CDK inhibitors
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
